Study Shows AI-Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 -- Bright Gene has recently revealed significant advancements in the development of their dual GLP-1/GIP receptor agonist, BGM0504. Detailed findings on the molecular design strategy and experimental outcomes were published online in the journal Scientific Reports, a sub-publication of Nature, on July 19, 2024. Bright Gene, an innovative pharmaceutical company listed as 688166.SH, aims to create top-tier pharmaceuticals that enhance global patient health.

The published article, titled "Molecular Dynamics Guided Optimization of BGM0504 Enhances Dual Target Agonism for Combating Diabetes and Obesity," outlines the successful development of BGM0504. This drug was designed with the assistance of artificial intelligence to serve as a dual GIP and GLP-1 receptor agonist, showing remarkable efficacy in both laboratory and live-animal studies. By employing AI-driven computer simulations, Bright Gene identified that the optimal interaction between glutamate residues on both GLP-1R and GIPR and the K20 residue of a peptide agonist provides enhanced activity. Notably, this critical interaction was not observable in cryo-electron microscopy studies.

To preserve the free amino group of the K20 residue, Bright Gene modified the acylation point to position 40 on BGM0504. This strategic design adjustment resulted in a threefold increase in the agonistic effects on both GLP-1R and GIPR. Consequently, this led to superior therapeutic outcomes in diabetic and obesity mouse models, underscoring the drug’s potential effectiveness.

Bright Gene is known for integrating active pharmaceutical ingredients (APIs) and formulations, blending both generic and innovative drugs to address global clinical needs. Currently, BGM0504 is in the advanced stages of Phase II clinical trials, targeting the treatment of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

Bright Gene’s commitment to scientific innovation and patient health is evident through the promising results of BGM0504. The company continues to leverage cutting-edge technology and molecular engineering to develop medications that address some of the most pressing health issues worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!